2型糖尿病患者对利拉鲁肽的治疗满意度调查及使用评价

Surveys on treatment satisfaction and evaluation of Liraglutide in type 2 diabetes patients

目的评价2型糖尿病患者对利拉鲁肽使用的治疗满意度，为临床用药提供参考。方法对2011年10月～2013年4月于辽宁中医药大学附属医院住院期间使用利拉鲁肽的115例2型糖尿病患者采用随机抽样方法抽取37例患者为调查对象，对利拉鲁肽使用前和使用后进行治疗满意度的问卷调查，采用SPSS17．0统计软件对数据进行分析。结果使用利拉鲁肽后糖尿病治疗的总体质量满意度由68．75％提高至96．88％，其中低血糖发生比率由原来25．00％偶尔发生降至9．38％偶尔发生，高血糖比率由62．50％降至15．63％，认为利拉鲁肽可以增加糖尿病治疗信心的患者占93．75％．95．74％患者认为利拉鲁肽在操作技术层面简单方便，28例（87．50％）患者认为医疗费用较原方案有所增加，使用初期有5例患者出现一过性恶心反应，1例患者出现一过性腹泻，其中有1例患者伴有一过性呕吐，此不良反应均在使用利拉鲁肽3～4d后明显减轻或消失。结论利拉鲁肽作为新型的肠促胰岛素类似物治疗2型糖尿病整体治疗满意度提高。但会产生短暂的胃肠道反应，且治疗费用有所提高，但对治疗满意度无太大影响。

Objective To evaluate the treatment satisfaction of Liraglutide in type 2 diabetes patients for clinical refer- ence. Methods Random sampling method was used to take samples from 115 type 2 diabetes patients, hospitalized from October 2011 to April 2013 in the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine and Li- raglutide was used, then 37 cases were selected. Among the patients questionnaire survey for treatment satisfaction of Liraglutide were conducted, and all data were analyzed with SPSS17.0. Results The overall treatment satisfaction after using Liraglutide, which played an significant role in curing diabetes, increased to 96.88% from 68.75%. Besides, the percentage of having hypoglycemia occasionally reduced to 9.38% from 25.00%, and the percentage of having hyper- glycemia reduced to 15.63% from 62.50%. The percentage of patients whose confidence of treating diabetes increased after using Liraglutide was 93.75%. 95.74% of the patients consider that it was easy to command the technological skills of using Liraglutide. The percentage of patients who thought the costs of treatment had been increased obviously was 87.50% （28 person）. In the beginning of the treatment, there were 5 patients who had the feeling of nausea, 1 who had a transient diarrhea, another who had a transient vomit. But these adverse reactions disappeared or eased after 3-4 days using of Liraglutide. Conclusion Although causing some the transient gastrointestinal reactions and leading higher medical costs, the satisfaction of Liraglutide as a new glucagon like peptide-1 analogue in the treatment of type 2 dia- betes grows dramatically.